Vitamin K2 supplementation can slow down coronary artery calcification in placebo-controlled study

Coagulation Profile BV are delighted to share that the results of the VitaK-CAC study have today been published in JAMA Cardiology (1). Working in close collaboration with the study investigators at Maastricht University Medical Center, Coagulation Profile BV are proud to have contributed our analytical expertise to a clinical study that will help advance the understanding of the mechanisms and management of cardiovascular disease.

The randomised, placebo-controlled Vitamin K-Coronary Artery Calcification (VitaK-CAC) study evaluated whether two years of daily supplementation with the vitamin K2 homologue menaquinone-7 (MK-7) could slow the progression of coronary artery calcification compared with placebo in patients with symptomatic coronary artery disease lesions. The results from analyses of 180 included patients show that those taking a daily tablet of 360 micrograms of MK7 had significantly less progression of coronary artery calcification and lower calcium mass after two years compared with those in the placebo arm. The patients taking MK-7 also had fewer non-calcified coronary plaques become partly calcified compared with placebo.

Coagulation Profile BV supported the VitaK-CAC study by performing analyses of dephosphorylated-uncarboxylated matrix Gla protein (dp ucMGP), a biomarker of vitamin K status and coronary artery calcification, using the IDS-iSYS InaKtif MGP assay (2). The study found that MK-7 supplementation was associated with favourable changes in dp ucMGP.

This collaboration reflects our ongoing commitment at Coagulation Profile BV to delivering high-quality biomarker and assay solutions to support translational and clinical research programmes. Find out how your development programme can benefit from our broad experience and comprehensive knowledge by contacting us at info@coagulationprofile.com or visiting www.coagulationprofile.com.

References:

1. Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two years of menaquinone-7 supplementation and coronary artery calcification: a randomized clinical trial. JAMA Cardiology. Published online June 10, 2026. https://jamanetwork.com/journals/jamacardiology/article-abstract/2850256

2. Delanaye, P, Krzesinski, JM, Warling, X, et al. Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol 15, 145 (2014). https://doi.org/10.1186/1471-2369-15-145